Results 21 to 30 of about 183 (86)

Upcoming treatments for morphea

Immunity, Inflammation and Disease, Volume 9, Issue 4, Page 1101-1145, December 2021., 2021
Morphea is a rare connective tissue disease with variable clinical presentations, all of which are characterized by inflammatory fibrosis. No cure for morphea exists, but advances in our understanding of the mediators and cellular pathways underlying fibrosis have revealed potential therapeutic targets.
Dan Wenzel, Nazgol‐Sadat Haddadi, Khashayar Afshari, Jillian M. Richmond, Mehdi Rashighi   +4 more
wiley   +1 more source

2547 Long-term response to treatment and disease recurrence in a prospective cohort of morphea patients

Journal of Clinical and Translational Science, 2018
OBJECTIVES/SPECIFIC AIMS: Morphea (localized scleroderma) is an autoimmune disease characterized that is widely thought to have a monophasic course, in which an initial period of inflammation (activity) ultimately results in scarring, atrophy, and ...
Stephanie Florez-Pollack, Jack C. O’Brien, Heidi T. Jacobe   +2 more
doaj   +1 more source

Sclerosing diseases of the skin

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 23, Issue 10, Page 1282-1301, October 2025.
Summary Sclerosing skin diseases comprise a group of distinct dermatological conditions characterized by fibrotic changes that may severely impair patients’ quality of life. These conditions often present with cutaneous manifestations and, in some cases, may extend to extracutaneous tissues, potentially resulting in significant morbidity and mortality.
Yasamin Kalantari, Katharina Meier, Kamran Ghoreschi, Maria Kinberger, Farzan Solimani   +4 more
wiley   +1 more source

Sklerosierende Erkrankungen der Haut

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 23, Issue 10, Page 1282-1303, October 2025.
Zusammenfassung Sklerosierende Hautkrankheiten sind eine Gruppe unterschiedlicher dermatologischer Erkrankungen, die durch fibrotische Veränderungen gekennzeichnet sind und die Lebensqualität der Patienten stark einschränken können. Diese Erkrankungen treten häufig mit kutanen Manifestationen auf und können in bestimmten Fällen auch extrakutanes Gewebe
Yasamin Kalantari, Katharina Meier, Kamran Ghoreschi, Maria Kinberger, Farzan Solimani   +4 more
wiley   +1 more source

Efficacy and Safety of Ablative Fractional CO2 Laser Therapy for Localized Scleroderma: A Comprehensive Bench‐to‐Bedside Approach

Dermatologic Therapy, Volume 2025, Issue 1, 2025.
Background Localized scleroderma (LS) is a disfiguring chronic inflammatory disease characterized by fibrosis of the skin and subcutaneous tissue. As the available therapeutic options are limited, developing effective and safe treatment protocols is crucial. Methods This study included both animal experiments and a single‐arm, open‐label clinical trial.
Ke Chai, Zehong Song, Bingsi Tang, Lou Lou, Ruixuan You, Yi Wei, Licong Liu, Ruixuan Zhu, Puyu Zou, Xinglan He, Zixin Pi, Ting Zeng, Yi Zhan, Zhuotong Zeng, Yaqian Shi, Xiangning Qiu, Rong Xiao, Suraiya Saleem   +17 more
wiley   +1 more source

Magnetic Resonance Imaging Evaluation in Patients with Linear Morphea Treated with Methotrexate and High‐Dose Corticosteroid

Dermatology Research and Practice, Volume 2018, Issue 1, 2018., 2018
Background. Morphea is an inflammatory disease of the connective tissue that may lead to thickening and hardening of the skin due to fibrosis. The aim of this study was to document magnetic resonance imaging (MRI) changes in patients with linear morphea who were treated with methotrexate (MTX) and high‐dose corticosteroid. Methods.
Mohammad Shahidi-Dadras, Fahimeh Abdollahimajd, Razieh Jahangard, Ali Javinani, Amir Ashraf-Ganjouei, Parviz Toossi, E. Helen Kemp   +6 more
wiley   +1 more source

Comparison of 3D facial photographs and clinical documentation in patients with craniofacial morphea

Skin Health and Disease, Volume 4, Issue 6, December 2024.
Craniofacial morphea (CM) is a rare autoimmune disease characterised by progressive atrophy of the skin and soft tissue of the face, resulting in facial asymmetry. With the involvement of varying practices in the care of patients with CM, consistent documentation of disease location and severity lack standardized evaluation.
Tyler T. Nguyen, Stephanie M. Cohen, Katharina S. Shaw, Fatma Dedeoglu, Ruth Ann Vleugels, Ingrid M. Ganske   +5 more
wiley   +1 more source

S2k guideline: Diagnosis and therapy of localized scleroderma

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 22, Issue 4, Page 605-620, April 2024.
Summary The updated S2k guideline deals with the diagnosis and therapy of localized scleroderma (LoS). LoS represents a spectrum of sclerotic skin diseases in which, depending on the subtype and localisation, structures such as adipose tissue, muscles, joints, and bones may also be affected.
Alexander Kreuter, Pia Moinzadeh, Maria Kinberger, Gerd Horneff, Margitta Worm, Ricardo N. Werner, Andreas Hammacher, Thomas Krieg, Jörg Wenzel, Michael Oeschger, Lisa Weibel, Robert Müllegger, Nicolas Hunzelmann   +12 more
wiley   +1 more source

S2k‐Leitlinie: Diagnostik und Therapie der zirkumskripten Sklerodermie

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 22, Issue 4, Page 605-621, April 2024.
Zusammenfassung Die vorliegende aktualisierte S2k‐Leitlinie befasst sich mit der Diagnostik und der Therapie der zirkumskripten Sklerodermie (ZS). Diese umfasst ein Spektrum sklerotischer Erkrankungen der Haut mit, je nach Subtyp und Lokalisation, möglicher Beteiligung von hautnahen Strukturen wie Fettgewebe, Muskulatur, Gelenke und Knochen. Ein Befall
Alexander Kreuter, Pia Moinzadeh, Maria Kinberger, Gerd Horneff, Margitta Worm, Ricardo N. Werner, Andreas Hammacher, Thomas Krieg, Jörg Wenzel, Michael Oeschger, Lisa Weibel, Robert Müllegger, Nicolas Hunzelmann   +12 more
wiley   +1 more source

Assessing the response of morphea and limited scleroderma to tranilast: a small prospective study comparing topical corticosteroids to a combination of topical corticosteroids and tranilast

Clinical, Cosmetic and Investigational Dermatology, 2018
Rowland Noakes Queensland Institute of Dermatology, Greenslopes Private Hospital Campus, Greenslopes, QLD, Australia Background: Scleroderma is traditionally managed with immunomodulatory agents such as methotrexate, mycophenolate mofetil and ...
Noakes R
doaj